The University of Glasgow has entered into a research collaboration with pharmaceutical company Eli Lilly and Company, that aims to discover and validate the next generation of drug targets for immunological diseases. The £4.6million research collaboration, due to last four years, will work across four diseases – psoriatic arthritis, rheumatoid arthritis, fibrosis and vasculitis – ...

This story continues at Glasgow University and Eli Lilly hook up to discover and validate drug targets

Or just read more coverage at Electronics Weekly